Abstract
Neisseria gonorrhoeae and Neisseria meningitidis are closely related and important human pathogens that cause distinct diseases of clinical significance. While N. meningitidis infrequently demonstrates antibiotic resistance, the rapid emergence of multidrug-resistant N. gonorrhoeae isolates emphasizes the urgency of novel therapeutics against this pathogen. Recently, repurposing of approved drugs and the therapeutic potential of natural compounds have been explored as alternative strategies to treat gonococcal infections. We screened 54 natural bioactive compounds and identified celastrol and pristimerin, two quinone-methide triterpenoids, which exhibited bactericidal activity against N. gonorrhoeae 1291. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) for 10 susceptible and multidrug-resistant N. gonorrhoeae strains ranged between 0.4-11.3 mg/L and 0.7-23.3 mg/L, respectively. Both compounds were also bactericidal against a diverse panel of N. meningitidis strains representing multiple serogroups. The MIC and MBC for N. meningitidis strains ranged between 1.4-23.3 mg/L and 1.4-46.5 mg/L, respectively. Pristimerin effectively cleared N. gonorrhoeae infection in transformed primary cervical epithelial cells without inducing cytotoxicity at biologically active concentrations. In contrast, celastrol exhibited a modest cytotoxic effect on the cells. In summary, we screened a library of bioactive compounds and identified the natural quinone-methide triterpenoids celastrol and pristimerin, as antimicrobial leads against pathogenic Neisseria species. These compounds represent promising scaffolds for the future development of therapeutics targeting gonorrhea.IMPORTANCENeisseria gonorrhoeae and Neisseria meningitidis cause clinically significant diseases, but rising multidrug-resistant N. gonorrhoeae creates an urgent need for new therapies. We screened 54 natural bioactive compounds from the NatureBank library and identified celastrol and pristimerin, two quinone-methide triterpenoids with notable bactericidal activity against susceptible and resistant N. gonorrhoeae, as well as diverse N. meningitidis serogroups. Celastrol showed stronger activity but limited selectivity and known toxicity, indicating a need for structural optimization. Pristimerin exhibited a favorable safety margin while maintaining antimicrobial potency. These findings highlight natural triterpenoids as promising scaffolds for lead optimization and development into novel antimicrobials to combat antibiotic-resistant gonorrhea.